TECX Tectonic Therapeutic Inc.

Oppenheimer reiterated $TECX Outperform-$80 and said -- We view the first clinical look at TX2100 as a positive step for TECX's hereditary hemorrhagic telangiectasia (HHT) program. $RHHBY $BMY NVS EWTX CYTK MRK GSK IBIO TENX Oppenheimer added—The healthy volunteer data show just what we wanted to see: single doses of IV/SC TX2100 were well-tolerated across all six cohorts, PK results confirm high affinity target engagement, and, together with animal model data, suggest an exposure range for upcoming investigation. Two studies in HHT patients, an open-label Phase 1b and a placebo-controlled Phase 2, are slated to begin by early next year. While investors remain focused on TX45's Phase 2 APEX trial in PH-HFpEF (top line early 1Q27), we see TX2100 shaping up as a second asset with a meaningful potential commercial opportunity (~75K US patients, no approved options; TX2100 has FDA Fast Track).